dusigitumab
Dusigitumab is a human monoclonal antibody designed for the treatment of cancer. It binds to IGF2. It was developed by MedImmune, which was acquired by AstraZeneca, using Xenomouse technology licensed from Abgenix. Its development has been discontinued. — Wikipedia
Clinical trial activity
4 trials · 2 clinical orgs · 0 marketing orgs
Earliest trial started Mar 1, 2009 (NCT00816361)
Timeline
Indications
Mechanism of action
- Insulin-like growth factor IINHIBITOR
IGF1 inhibitor
Selectively binds to human IGF-I and IGF-II, and inhibits their ability to trigger IGFIR (Insulin-like growth factor 1 receptor) and INSR (insulin receptor) signaling without affecting insulin activation of INSR.
- Insulin-like growth factor IIINHIBITOR
IGF2 inhibitor
Selectively binds to human IGF-I and IGF-II, and inhibits their ability to trigger IGFIR (Insulin-like growth factor 1 receptor) and INSR (insulin receptor) signaling without affecting insulin activation of INSR.
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaDusigitumab ↗
- ChEMBLCHEMBL2109355 ↗
Also known as
- dusigitumab
- dusigitumab
- medi-573
- medi-573
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01498952 | Phase 1 | Jan 1, 2012 | MedImmune |
| NCT01340040 | Phase 1 | Jul 1, 2011 | AstraZeneca, MedImmune |
| NCT01446159 | Phase 2 | Jun 13, 2011 | MedImmune |
| NCT00816361 | Phase 1 | Mar 1, 2009 | MedImmune |
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| MedImmune | For profit | 4 | 3 | 2 | 2009 |
| AstraZeneca | For profit | 1 | 1 | 1 | 2011 |